Severity
Moderate
FDA Drug recall · Reported March 14, 2018
Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.
Hospira Inc. A Pfizer Company recalled Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx… - a moderate-severity action.
Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx… was recalled by Hospira Inc. A Pfizer Company in March 14, 2018. Reason: Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.. Check the official notice for the remedy. Verify recall #D-0576-2018 with the FDA Drug before acting.
The recall
Hospira Inc. A Pfizer Company issued this moderate-severity FDA Drug recall-Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal..
Sourced from official FDA Drug enforcement records. Verify recall #D-0576-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0576-2018) was formally reported on March 14, 2018, with the manufacturer initiating the action on February 20, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Hospira Inc. A Pfizer Company is listed as the recalling firm, operating out of Mcpherson, KS. Federal records list the affected scope as a) 137,975 vials; b) 40,143 vials.
The documented reason for this recall is: Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal. Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
a) 137,975 vials; b) 40,143 vials
Related Recalls
6
5 from same agency
Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx only, labeled as a) Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2267-20; and b) NOVAPLUS, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2267-25.
Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0576-2018 |
| Date reported | March 14, 2018 |
| Date initiated | February 20, 2018 |
| Recalling firm | Hospira Inc. A Pfizer Company |
| Firm location | Mcpherson, KS |
| Affected scope | a) 137,975 vials; b) 40,143 vials |
| Distribution | Nationwide in the USA and Puerto Rico. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 14, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.